168 related articles for article (PubMed ID: 34982285)
1. Dissolution Challenges Associated with the Surface pH of Drug Particles: Integration into Mechanistic Oral Absorption Modeling.
Hens B; Seegobin N; Bermejo M; Tsume Y; Clear N; McAllister M; Amidon GE; Amidon GL
AAPS J; 2022 Jan; 24(1):17. PubMed ID: 34982285
[TBL] [Abstract][Full Text] [Related]
2. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
[TBL] [Abstract][Full Text] [Related]
3. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
[TBL] [Abstract][Full Text] [Related]
4. Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 1: Fasted State Conditions.
Bermejo M; Paixão P; Hens B; Tsume Y; Koenigsknecht MJ; Baker JR; Hasler WL; Lionberger R; Fan J; Dickens J; Shedden K; Wen B; Wysocki J; Löbenberg R; Lee A; Frances A; Amidon GE; Yu A; Salehi N; Talattof A; Benninghoff G; Sun D; Kuminek G; Cavanagh KL; Rodríguez-Hornedo N; Amidon GL
Mol Pharm; 2018 Dec; 15(12):5454-5467. PubMed ID: 30372084
[TBL] [Abstract][Full Text] [Related]
5. Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 2: Fed State.
Paixão P; Bermejo M; Hens B; Tsume Y; Dickens J; Shedden K; Salehi N; Koenigsknecht MJ; Baker JR; Hasler WL; Lionberger R; Fan J; Wysocki J; Wen B; Lee A; Frances A; Amidon GE; Yu A; Benninghoff G; Löbenberg R; Talattof A; Sun D; Amidon GL
Mol Pharm; 2018 Dec; 15(12):5468-5478. PubMed ID: 30417648
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space.
Wang M; Heimbach T; Zhu W; Wu D; Reuter KG; Kesisoglou F
AAPS J; 2024 Jun; 26(4):69. PubMed ID: 38862807
[TBL] [Abstract][Full Text] [Related]
7. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
[TBL] [Abstract][Full Text] [Related]
8. In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.
Hens B; Pathak SM; Mitra A; Patel N; Liu B; Patel S; Jamei M; Brouwers J; Augustijns P; Turner DB
Mol Pharm; 2017 Dec; 14(12):4321-4333. PubMed ID: 28817288
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions.
Koenigsknecht MJ; Baker JR; Wen B; Frances A; Zhang H; Yu A; Zhao T; Tsume Y; Pai MP; Bleske BE; Zhang X; Lionberger R; Lee A; Amidon GL; Hasler WL; Sun D
Mol Pharm; 2017 Dec; 14(12):4295-4304. PubMed ID: 28937221
[TBL] [Abstract][Full Text] [Related]
10. Integrating Drug- and Formulation-Related Properties With Gastrointestinal Tract Variability Using a Product-Specific Particle Size Approach: Case Example Ibuprofen.
Cristofoletti R; Hens B; Patel N; Esteban VV; Schmidt S; Dressman J
J Pharm Sci; 2019 Dec; 108(12):3842-3847. PubMed ID: 31539541
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption.
Laisney M; Heimbach T; Mueller-Zsigmondy M; Blumenstein L; Costa R; Ji Y
J Pharm Sci; 2022 Jan; 111(1):274-284. PubMed ID: 34678270
[TBL] [Abstract][Full Text] [Related]
12. Differing disintegration and dissolution rates, pharmacokinetic profiles and gastrointestinal tolerability of over the counter ibuprofen formulations.
Bjarnason I; Sancak O; Crossley A; Penrose A; Lanas A
J Pharm Pharmacol; 2018 Feb; 70(2):223-233. PubMed ID: 29238984
[TBL] [Abstract][Full Text] [Related]
13. A Novel Approach to Justify Dissolution Differences in an Extended Release Drug Product using Physiologically Based Biopharmaceutics Modeling and Simulation.
Aishwarya R; Murthy A; Ahmed T; Chachad S
J Pharm Sci; 2022 Jun; 111(6):1820-1832. PubMed ID: 35217007
[TBL] [Abstract][Full Text] [Related]
14. A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP.
Bermejo M; Hens B; Dickens J; Mudie D; Paixão P; Tsume Y; Shedden K; Amidon GL
Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31963448
[TBL] [Abstract][Full Text] [Related]
15. Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products Based on Physiologically Based Pharmacokinetic Modeling: An In-Depth Analysis.
Li X; Yang Y; Zhang Y; Wu C; Jiang Q; Wang W; Li H; Li J; Luo C; Wu W; Wang Y; Zhang T
Mol Pharm; 2019 Sep; 16(9):3780-3790. PubMed ID: 31398041
[TBL] [Abstract][Full Text] [Related]
16. Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis.
Salehi N; Kuminek G; Al-Gousous J; Sperry DC; Greenwood DE; Waltz NM; Amidon GL; Ziff RM; Amidon GE
Mol Pharm; 2021 Sep; 18(9):3326-3341. PubMed ID: 34428047
[TBL] [Abstract][Full Text] [Related]
17. Use of biorelevant dissolution and PBPK modeling to predict oral drug absorption.
Kaur N; Narang A; Bansal AK
Eur J Pharm Biopharm; 2018 Aug; 129():222-246. PubMed ID: 29879527
[TBL] [Abstract][Full Text] [Related]
18. In vitro-in vivo-in silico approach in biopharmaceutical characterization of ibuprofen IR and SR tablets.
Beloica S; Cvijić S; Bogataj M; Parojčić J
Eur J Pharm Sci; 2015 Jul; 75():151-9. PubMed ID: 25861718
[TBL] [Abstract][Full Text] [Related]
19. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
[TBL] [Abstract][Full Text] [Related]
20. Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure.
Mukherjee D; Chiney MS; Shao X; Ju TR; Shebley M; Marroum P
Biopharm Drug Dispos; 2022 Jun; 43(3):98-107. PubMed ID: 35405765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
